Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Aim(s): The experience of 12 centers in Spain with this scheme is presented.
Materials and methods: We retrospectively reviewed patients with NETs G1-2 of any origin treated with capecitabine (750-1000 mg/m2 twice daily days 1-14) and temozolomide (150-200 mg/m2 days 10-14) every 28 days, from June 2009 to August 2015.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
Crespo G H
, Jimenez-Fonseca P
, Custodio A
, Lopez C
, Carmona-Bayonas A
, Alonso V
, Navarro M
, Aller J
, Sevilla I
, Gajate P
, Alonso T
, Matos I
, Capdevila J
, Nieto B
, Barriuso J
To read results and conclusion, please login ...
Further abstracts you may be interested in